From Phase III oncology to rare disease recruitment, see how TrialVyx is shortening enrollment timelines and reducing screen failure rates in active clinical programs.
A sponsor managing a Phase III immunotherapy trial with 14 sites used TrialVyx to move from a 22-month projected enrollment to 11 months actual — without adding a single new site.
With an estimated US prevalence under 1 in 100,000, locating eligible patients for a rare metabolic disorder trial was the primary obstacle. TrialVyx's phenotype engine scanned EHRs across 7 sites to surface a candidate pool that would have taken 18+ months to build manually.
Every deployment starts with a 90-day pilot. We'll scope the protocol, activate your sites, and measure results against your pre-deployment baseline.
Start a Pilot